Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib and Niraparib as Neoadjuvant Therapy in HR+ HER2- Breast Cancer
NCT04481113Phase 1Completed
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Jun 2021
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abemaciclib and niraparib in breast cancer, sponsored by OHSU Knight Cancer Institute. Primary endpoints: Dose Limiting Toxicities at 4 weeks and Adverse Events at 7 months. Started Jun 2021; status: completed.
02
Drugs
abemaciclibniraparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04481113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04481113.